The Epidemic Monitor based on Artificial Intelligence (EMAI) is a project led by Dr. Youcef Azeli, the principal investigator and Dr. Eduard Llobet, and Dr. Albert Fernandez. The project represents a remarkable achievement in the realm of public health and infectious disease management.
Developed by the Urgent and Emergency Research Group (GRUEM) at Pere Virgili Health Research Institute, Rovira i Virgili University and Sant Joan de Reus Hospital, EMAI stands as a beacon of innovation and progress in combating the spread of viral respiratory infection, which is capable to detect massively the disease using only the symptoms.
Viral respiratory infections have long been a persistent challenge in healthcare, necessitating swift and accurate detection to control transmission effectively. Recognizing this imperative, the EMAI project was conceived to pioneer a non-invasive epidemic outbreak screening system based on artificial intelligence.
EMAI’s innovative approach to epidemic monitoring offers a multifaceted solution to the challenges posed by infectious diseases. By leveraging advanced AI algorithms, EMAI can swiftly and accurately identify symptoms, enabling timely intervention to isolate and protect vulnerable individuals. This proactive approach not only saves lives but also reduces the burden on healthcare systems and minimizes economic costs associated with illness-related absenteeism.
During the 2nd wave of COVID-19, an EMAI system has been installed at the Emergency Department of Sant Joan de Reus Hospital to detect the risk of suffering the disease in the population. By hydroalcoholic gel with a QR, which provides access to a test that evaluates the ability to identify the scent of the product and eight symptoms compatible with the disease. Using artificial intelligence techniques, it instantly reduces the risk of having COVID-19, being the world’s first patented mass screening system for COVID-19 cases.
According to the results of the experiment, EMAI’s impact extends beyond the laboratory, making a tangible difference in public health and occupational settings. By disrupting transmission chains in both residential and workplace environments, EMAI has emerged as a powerful tool in the fight against infectious diseases. Its holistic approach to epidemic monitoring, coupled with its robust technological infrastructure, positions EMAI as a case of success in epidemic management and a beacon of hope for future innovations in healthcare.
EMAI has patented his project at European phase WO2022258847A1.
01 d'September de 2021
